.2 channels and PKA in the transverse tubules of isolated ventricular myocytes. Site-directed mutagenesis studies reveal that AKAP15 directly interacts with the distal C terminus of the cardiac Ca V1.2 channel via a leucine zipper-like motif. Disruption of PKA anchoring to Ca V1.2 channels via AKAP15 using competing peptides markedly inhibits the ␤-adrenergic regulation of CaV1.2 channels via the PKA pathway in ventricular myocytes. These results identify a conserved leucine zipper motif in the C terminus of the Ca V1 family of Ca 2؉ channels that directly anchors an AKAP15-PKA signaling complex to ensure rapid and efficient regulation of L-type Ca 2؉ currents in response to ␤-adrenergic stimulation and local increases in cAMP.
V
oltage-gated L-type calcium (Ca 2ϩ ) channels play a pivotal role in the regulation of a wide range of cellular processes, including membrane excitability, Ca 2ϩ homeostasis, protein phosphorylation, and gene regulation. In cardiac myocytes, Ca 2ϩ influx through Ca V 1.2 channels contributes to the plateau phase of the cardiac action potential and is responsible for initiating excitation-contraction coupling (1) (2) (3) . Voltage-gated L-type Ca 2ϩ channels are multisubunit complexes composed of a poreforming ␣ 1 subunit and auxiliary ␤ and ␣ 2 ␦ subunits (4). In cardiac muscle, a distinct ␣ 1 subunit (␣ 1 1.2a) (5, 6) , an ␣ 2 ␦ subunit (7) , and several isoforms of ␤ subunits [␤ 1b and ␤ 2a-d (8) (9) (10) (11) ] have been identified and implicated to form the Ca V 1.2 channel. As for the skeletal muscle Ca V 1.1 channel (12, 13) , two size forms of the ␣ 1 1.2a subunit of Ca V 1.2 channels, Ϸ240 and 210 kDa, are present in cardiac muscle and differ by truncation at the C terminus (14) . Whereas the majority of Ca 2ϩ channel ␣ 1 subunits isolated from cardiac muscle are truncated (11, 14, 15) , the cleaved distal C terminus remains associated with the truncated ␣ 1 subunit of Ca V 1.2 after proteolytic processing, and peptides derived from it can regulate channel activity (16, 17) . Ca V 1.2 channels can be modulated by a variety of receptormediated processes, including stimulation through activation of the ␤-adrenergic receptor͞cAMP signaling pathway (4, (18) (19) (20) (21) . Activation of ␤-adrenergic receptors increases cardiac L-type Ca 2ϩ currents through cAMP-dependent protein kinase A (PKA)-mediated phosphorylation of the Ca V 1.2 channel protein and͞or associated proteins (22, 23) . As for skeletal muscle Ca v 1.1 channels (24, 25) , both the ␣ 1 and ␤ subunits of Ca V 1.2 channels are substrates for phosphorylation by PKA (14, (26) (27) (28) . PKA phosphorylates only the full-length form of the ␣ 1 subunit, on a single site containing serine 1928 in the C-terminal domain (14, 26) . In contrast, the C-terminal truncated ␣ 1 subunit is not a substrate for phosphorylation by PKA in vitro (14, 26) . Ca V 1.2 channels consisting of only ␣ 1 subunits can be regulated by PKA, implicating phosphorylation of serine 1928 in channel regulation (29, 30) . Mutation of serine 1928 to alanine prevents PKAdependent phosphorylation and the low level of functional modulation of Ca V 1.2 channels that is observed in heterologous expression systems (31) .
The importance of PKA anchoring through the association with A kinase-anchoring proteins (AKAPs) has recently been established in the regulation of L-type Ca 2ϩ channels. AKAPs belong to a family of functionally related proteins that contain a targeting domain that directs the AKAP to a specific subcellular compartment or substrate and a kinase-anchoring domain containing an amphipathic ␣ helix that binds the regulatory (R) subunit dimer of PKA (32) (33) (34) (35) . Intracellular dialysis of ''kinaseanchoring inhibitor peptides,'' which competitively inhibit PKA-AKAP interactions, effectively inhibits PKA-dependent increase of Ca 2ϩ channel activity in skeletal muscle cells (36, 37) and cardiac myocytes (31) . A low molecular weight AKAP, AKAP15 (refs. 38 and 39; also known as AKAP18 and AKAP7; refs. 40 and 41; bioinfo.cnio.es͞cgi-bin͞db͞genecards͞carddisp? AKAP7) has been identified as the anchoring protein that targets PKA to Ca V 1.1 channels in skeletal muscle. In contrast, in the brain, PKA is anchored near Ca V 1.2 channels via the microtubule-associated protein MAP2B (42) . Because MAP2B is not expressed in the heart, it is not a likely candidate for recruiting PKA to cardiac Ca V 1.2 channels.
Insight into the molecular mechanisms underlying the targeting of kinases and phosphatases to ion channels has recently emerged. Marx et al. (43) identified a novel role of atypical leucine zipper (LZ) motifs in targeting kinases and phosphatases to the ryanodine-sensitive Ca 2ϩ -release channel of the sarcoplasmic reticulum. Similarly, we found that AKAP15 targets PKA to the C terminus of skeletal muscle Ca V 1.1 channels through modified LZ interactions (44) . Disruption of the LZ interaction between AKAP15 and the C-terminal domain of Ca V 1.1 channels with a competing peptide effectively inhibits PKA-dependent potentiation of L-type Ca 2ϩ channel activity in skeletal muscle cells (44) . Sequence alignment of the LZ-like region of Ca V 1.1 with other members of the Ca V 1 channel family reveals a striking conservation of LZ-like motifs, suggesting that AKAP15 may also target PKA to Ca V 1.2 channels. Here, we report that AKAP15 coimmunoprecipitates and colocalizes with Ca V 1.2 channels in rat ventricular myocytes. Site-directed mutagenesis studies reveal that AKAP15 directly interacts with the C terminus of the cardiac Ca V 1.2 channel via an LZ-like interaction, similar to that identified in skeletal muscle. Disruption of PKA anchoring to Ca V 1.2 channels via AKAP15, using competing peptides, markedly inhibits PKA regulation of Ca V 1.2 channels activated by ␤-adrenergic receptors in ventricular myocytes. Our results imply that PKA anchored directly to the Ca V 1.2 channel by AKAP15 via an LZ motif is required for regulation of Ca 2ϩ channels in cardiac myocytes by the sympathetic nervous system.
Experimental Procedures
Antibodies and Peptides. Rabbit polyclonal anti-CNC1 and anti-CH1 antibodies were generated against peptides corresponding to residues 821-838 in the intracellular loop between domains II and III (CNC1) and residues 2155-2171 (CH1) in the distal C terminus of Ca V 1.2a, respectively, and characterized as described (14) . A chicken polyclonal anti-CNC1 antibody was generated against peptides corresponding to residues 823-838 [TTKIN-MDDLQPSENEDKS(C)] in the intracellular loop between domains II and III of Ca V 1.2a (26) . The cysteine residue was added to the C terminus of the peptide to facilitate crosslinking. The peptide was synthesized, purified, coupled to keyhole limpet hemocyanin, and used for immunization of chickens (Affinity BioReagents, Neshanic Station, NJ). The resulting antibody was affinity-purified on peptide columns as described (45) , and specificity of the antibody was confirmed by immunoblotting. Anti-AKAP15 antibodies and RII-biotin protein were prepared as described (39) . Anti-RII␣ antibody against the type II␣ regulatory subunit of PKA was kindly provided by G. Stanley McKnight (University of Washington). Monoclonal anti-Myc antibody was purchased from Invitrogen. AKAP15 LZ (38-54) (acetyl-ENAVLKAVQQYLEETQN-amide) and AKAP15 LZM (38) (39) (40) (41) (42) (43) (44) (45) (46) (47) (48) (49) (50) (51) (52) (53) (54) peptides (acetyl-ENAVAKAVQQYAEETQN-amide) were synthesized and purified by Genemed Biotechnologies (South San Francisco, CA). PKI(5-24)-amide was obtained from Peninsula Laboratories, and HT31 peptide was synthesized and purified as described (38) . (5) was constructed by incorporating the myristoylation and palmitoylation sequence (MGQLCC) of AKAP15 onto the N terminus of the Ca V 1.2 ABD with specific primers by PCR and cloned in frame into pcDNA3mycHisA. Ca V 1.2 ABD (LZm) incorporating mutations I2073A, F2080A, and I2087A was constructed by using PCR overlap extension and cloned into pcDNA3mycHisA. AKAP15 LZM was generated as described (44) . The orientation and reading frame of all constructs were confirmed by DNA sequencing.
Expression of CaV1.2 Channels and AKAP15 in tsA-201 Cells. TsA-201 cells were cultured in DMEM͞Ham's F-12 supplemented with 10% FBS, 100 units͞ml penicillin, and streptomycin plated on 15-cm dishes. Cells were transfected with 30-50 g of an equimolar ratio of expression plasmid cDNA by using the calcium phosphate method. For coexpression of AKAP15 with the full-length Ca V 1.2 channel, cDNA encoding the Ca 2ϩ channel subunits ␣ 1 1.2a, ␤ 1b , and ␣ 2 ␦ were cotransfected with AKAP15. After 48 h, cells were washed in PBS, solubilized in ice-cold bRIA (50 mM Tris⅐HCl, pH 7.4͞150 mM NaCl͞1 mg/ml BSA͞5 mM NaF͞1 mM EGTA͞5 mM EDTA͞1% Triton X-100͞plus protease inhibitors), and rotated at 4°C for 30 min. Unsolubilized material was removed by centrifugation, and the solubilized extracts containing AKAP15 and Ca V 1.2 were frozen for further analysis.
Preparation of Rat Heart Extracts. Hearts from adult male Wistar rats were pulverized under liquid N 2 and homogenized in buffer containing 20 mM Tris, 150 mM NaCl, 10 mM EGTA, 10 mM EDTA (pH 7.4), plus protease inhibitors. Homogenates were centrifuged at 8,900 ϫ g at 4°C to remove debris, and membranes were collected by ultracentrifugation at 100,000 ϫ g (4°C) for 45 min. Membranes were solubilized in homogenization buffer containing 1% digitonin for 30 min at 4°C, and insoluble material was removed by centrifugation.
Coimmunoprecipitation Experiments. Rat heart and transfected tsA-201 extracts were precleared with either protein A-or G-Sepharose. Precleared extracts were incubated with either 10 g of affinity-purified Ca V 1.2 channel antibody (anti-CNC1), 10 g of rabbit IgG, 2 g of anti-Myc antibody, or 2 g of mouse IgG for 3 h at 4°C, followed by the addition of protein A-or G-Sepharose (5 mg) for an additional 2 h. Immune complexes bound to the Sepharose beads were washed extensively, and proteins were separated by SDS͞PAGE, transferred to nitrocellulose, and analyzed by immunoblotting. Ca V 1.2 channel protein was detected with the anti-CNC1 antibody. Myc-tagged NAc-Ca V 1.2 ABD was detected by using monoclonal anti-Myc antibody (Invitrogen). For AKAP15 detection, immunoblots were probed by using an anti-AKAP15 antibody or the RIIbiotin overlay assay (38) . Each immunoprecipitation experiment was repeated at least three times.
Cell Isolation. Ventricular myocytes were isolated from male Wistar rats (201-225 g) as described (46) and maintained at 37°C until use.
Immunocytochemistry. For double-labeling studies, ventricular myocytes were plated on laminin-coated glass coverslips and incubated (5% CO 2 , 37°C) for Ϸ2 h. Myocytes were fixed with 4% paraformaldehyde for 30 min, rinsed with 0.1 M Trisbuffered saline (TBS) and blocked sequentially with 2% avidin and 2% biotin. For double-labeling, myocytes were incubated overnight at 4°C with the following primary antibodies (diluted in 10% goat serum and 0.2% Triton X-100 in TBS): chicken anti-CNC1 and anti-CH1, chicken anti-CNC1 and anti-AKAP15, and chicken anti-CNC1 and anti-RII␣. Myocytes were then rinsed in TBS and incubated with biotinylated chicken antibody against chicken IgY (Vector Laboratories) for 2 h at room temperature to label the chicken anti-CNC1, rinsed, and then incubated with avidin D fluorescein (Vector Laboratories). After extensive washing (12 ϫ 5 min TBS), myocytes were next incubated with biotinylated antibody against rabbit IgG (to label AKAP15 and CH1) or goat IgG (to label RII␣) overnight at 4°C, rinsed, and then incubated with avidin D Texas red (Vector Laboratories) for 2 h at room temperature. After final washes, coverslips were mounted on slides by using Vectashield (Vector Laboratories). Cells were viewed by using a Bio-Rad MRC 600 confocal microscope in the W. M. Keck Imaging Facility. Control experiments were routinely performed to exclude the possibility of nonspecifc labeling, crossreactivity of secondary antibodies with primary antibodies, or bleed-through from one channel to the other.
Electrophysiology. Whole-cell Ca 2ϩ currents (I Ca ) were recorded at room temperature from rod-shaped, striated, Ca 2ϩ -tolerant myocytes (46) within 1-10 h of isolation. The extracellular bath solution contained: 140 mM TEA-Cl, 2 mM MgCl 2 , 1.8 mM CaCl 2 , 10 mM Hepes, and 10 mM glucose (pH 7.4). Patch pipettes (1-1.5 M⍀) were filled with an intracellular solution containing 100 mM CsCl, 20 mM TEA-Cl, 1 mM MgCl 2 , 5 mM MgATP, 10 mM Hepes, and 10 mM EGTA (pH 7.3). Series resistance ranged between 3 and 6 M⍀ (60-80% compensated), and recordings were discarded if the series resistance was Ͼ6 M⍀ before compensation. I Ca was elicited by either a repetitive train of 300-ms depolarizing pulses to 0 mV or a series of 10-mV depolarizing pulses to different test potentials (Ϫ40 to ϩ60 mV) from a holding potential of Ϫ40 mV. I Ca was measured as the difference between the peak inward current and the current at the end of the test pulse. Membrane capacitance was measured by integrating the capacitance current recorded during a 10-mV hyperpolarizing pulse from a holding potential of Ϫ40 mV. Currents were recorded with an Axopatch 200B amplifier (Axon Instruments, Union City, CA) and sampled at 5 kHz after anti-alias filtering at 2 kHz. Data acquisition and command potentials were controlled by PCLAMP software (v8.0, Axon Instruments), and data were stored for later off-line analysis. HT31, AKAP15 LZ (38) (39) (40) (41) (42) (43) (44) (45) (46) (47) (48) (49) (50) (51) (52) (53) (54) , and AKAP15 LZM (38-54) peptides were prepared and used as described (44) . The effect of isoproterenol (1 M) on I Ca in the absence and presence of peptides was examined 10-15 min after establishing the whole-cell configuration. All data are expressed as the mean Ϯ SE of n cells. Statistical significance was tested by using Student's t test. Values of P Ͻ 0.01 were considered significant.
Results and Discussion
Coimmunoprecipitation of AKAP15 with CaV1.2 Channels. AKAP15 targets PKA to the C terminus of skeletal muscle Ca V 1.1 channels through modified LZ interactions (44) . Sequence alignment of the LZ-like region of Ca V 1.1 with other members of the Ca V 1 family revealed a striking conservation of LZ-like motifs (Fig. 1A) , including the cardiac Ca V 1.2 channel, raising the possibility that AKAP15 may also target PKA to Ca V 1.2 channels. To examine the possibility that AKAP15 associates with cardiac Ca V 1.2 channels, immunoprecipitation experiments were performed from rat heart extracts. Ca V 1.2 channels were immunoprecipitated with anti-CNC1 and assayed for coimmunoprecipitation of AKAP15 by immunoblotting. Fig. 1B shows that AKAP15 coimmunoprecipitated with Ca V 1.2 channels (Fig.  1B, lane 2) . The interaction between AKAP15 and the Ca 2ϩ channel was specific because AKAP15 was excluded from precipitates obtained with control IgG (Fig. 1B, lane 3) . Furthermore, whereas other AKAPs were detected in rat heart extracts by using the RII overlay assay (e.g., mAKAP and yotiao), these AKAPs failed to coimmunoprecipitate with Ca V 1.2 channels (data not shown).
To verify the interaction between AKAP15 and Ca V 1.2 channels, immunoprecipitation experiments were performed in transfected cells. TsA-201 cells were cotransfected with equimolar ratios of Ca 2ϩ channel ␣ 1 1.2a, ␤ 1b , and ␣ 2 ␦ subunits and AKAP15. Cell lysates were immunoprecipitated with anti-CNC1 or control IgG, and the immunoprecipitated AKAP15 protein was detected with an anti-AKAP15 antibody. Fig. 2A shows that AKAP15 also coimmunoprecipitated with Ca V 1.2 channels when heterologously expressed in tsA-201 cells. Thus, AKAP15 may bind directly to the Ca V 1.2 channel complex. Having established that AKAP15 associates with the cardiac Ca V 1.2 channel, we next tested the hypothesis that AKAP15 directly interacts with the C terminus of Ca V 1.2 via an LZ interaction similar to that identified in the skeletal muscle Ca V 1.1 channel (Fig. 1 A and ref. 44) . A myc-epitope-tagged C-terminal construct of Ca V 1.2 containing the putative AKAP15-binding domain (Ca V 1.2 ABD, residues 2057-2115) was generated, and its ability to interact with AKAP15 was examined by coimmunoprecipitation experiments in transfected tsA-201 cells, as described (44) . Lysates of tsA-201 cells coexpressing AKAP15 and the Ca V 1.2 ABD were immunoprecipitated with an anti-Myc antibody or control IgG, and the immunoprecipitated AKAP15 was detected by using the anti-AKAP15 antibody (Fig. 2) . Immunoblotting of cell lysates with anti-AKAP15 or anti-myc antibody demonstrated robust expression of AKAP15 and the Ca V 1.2 ABD, respectively (Fig. 2B) . Fig. 2B shows that AKAP15 coimmunoprecipitated with the Ca V 1.2 ABD. To test the hypothesis that AKAP15 binds to the Ca V 1.2 ABD via an LZ interaction, isoleucine and phenylalanine residues at positions 2073, 2087, and 2080 were mutated to alanine to generate Ca V 1.2 ABD LZm , and the leucine residues at positions 42 and 49 in AKAP15 were mutated to alanine to generate AKAP15 LZm as described (44) . Lysates of tsA-201 cells coexpressing wtAKAP15 or AKAP15 (LZm) with either the Ca V 1.2 ABD or Ca V 1.2 ABD (LZm) were immunoprecipitated with an anti-myc antibody or control IgG, and the immunoprecipitated proteins were detected by using the RII-biotin overlay assay, which gives robust labeling of both wild-type and mutant AKAP15. We found that binding of either AKAP15 (LZm) to wtCa V 1.2 ABD, or wtAKAP15 to Ca V 1.2 ABD (LZm) was substantially reduced (Fig. 2B) . Binding of AKAP15 (LZm) to Ca V 1.2 ABD (LZm) was not detectable (Fig. 2B) . Thus, the LZ motif in the distal C terminus of Ca V 1.2 is required for AKAP15 targeting of PKA to the Ca 2ϩ channel.
Colocalization of CaV1.2 Channels, AKAP15, and the Regulatory Subunit of PKA in the Transverse Tubules of Rat Ventricular Myocytes. We next determined the subcellular localization of AKAP15 in rat ventricular myocytes and examined whether AKAP15, PKA, and Ca V 1.2 channels colocalize in vivo by using double-labeling immunofluorescence techniques and chicken anti-CNC1, which specifically recognizes Ca V 1.2 (Fig. 2C) . Ca V 1.2 channels (Fig.  3A , green) and AKAP15 (Fig. 3B, red) are concentrated in the transverse tubules, as revealed by the regular, punctate pattern of the two proteins along the z-line and throughout the depth of the cell. A clear colocalization of these proteins is revealed when images of their respective staining patterns are merged (Fig. 3C,  yellow) . These results confirm our biochemical data suggesting that AKAP15 and Ca V 1.2 channels are associated and support a role for AKAP15 in targeting PKA to Ca 2ϩ channels in the heart. To examine whether PKA colocalizes with AKAP15 and Ca V 1.2 channels, myocytes were double-labeled with antibodies specific for the Ca V 1.2 channel and the Type II␣ regulatory subunit of PKA (anti-RII␣, Fig. 3 D-F) . Whereas a clear overlap of Ca V 1.2 channel and RII␣ staining was detected along the z-line in the transverse tubules (Fig. 3F) , a significant portion of RII␣ staining did not colocalize with Ca V 1.2 channels, as revealed by red staining in Fig. 3F . These findings suggest that a pool of PKA containing RII␣ subunits is associated with AKAP15 and Ca V 1.2 channels, but PKA containing RII␣ subunits is also targeted to other compartments of the cells, as expected from the many physiological effects of PKA in cardiac cells. Whereas PKA containing Type I regulatory subunits (RI) is also highly expressed in the rodent heart, it is differently distributed than RII␣-containing PKA (47) .
Two size forms of the ␣ 1 subunit of Ca V 1.2 channels, Ϸ240 and 210 kDa, are present in cardiac muscle and differ by truncation at the C terminus (14) . Interestingly, the AKAP15 interaction site in Ca V 1.2 channels is located in the C-terminal domain that is cleaved in the truncated form of Ca V 1.2. Therefore, Ca V 1.2 channels may have intact, truncated and bound, or truncated and dissociated C-terminal domains in vivo. To examine the subcellular localization pattern of Ca V 1.2 channels and the distal C terminus, myocytes were double-labeled with anti-CNC1, which recognizes both full-length and truncated Ca V 1.2 channels, and anti-CH1, which recognizes only the distal C terminus. Fig. 3 G and H shows that the staining pattern for anti-CNC1 (Fig. 3G,  green) was indistinguishable from that of anti-CH1 [ Fig. 3 H (red) and I (merged)]. Evidently, the distal C-terminal domain containing the Ca V 1.2 ABD is present in intact ventricular myocytes and colocalized with the remainder of the Ca V 1.2 channel protein in the transverse tubules at the junctions with the sarcoplasmic reticulum. Taken together, these data show that Ca V 1.2 channels, their distal C-terminal domain, AKAP15, and PKA colocalize in the t-tubules of ventricular myocytes.
Disruption of PKA͞AKAP15 Anchoring to Cav1.2 Channels with Competing Peptides. It is well established that activation of ␤-adrenergic receptors by isoproterenol increases Ca V 1.2 channel activity through activation of a cAMP-and PKA-dependent pathway (19, 20, 23) . The results presented above demonstrate that AKAP15 directly associates with the C terminus of the cardiac Ca V 1.2 channel through modified LZ motifs and colocalizes with Ca V 1.2 channels in ventricular myocytes. To examine the functional significance of AKAP15 binding to the C terminus of Ca V 1.2, we used a competing peptide approach to examine the functional importance of disrupting anchoring of PKA and AKAP15 to Ca V 1.2 channels in PKA regulation of Ca 2ϩ currents in rat ventricular myocytes. Fig. 4A shows superimposed records of I Ca from a typical myocyte recorded at 0 mV from a holding potential of Ϫ40 mV before (filled circles) and after (open circles) 5-min exposure to isoproterenol (1 M). Isoproterenol markedly increased the amplitude of I Ca and caused a 9.1 Ϯ 0.8-mV hyperpolarizing shift in the current-voltage (I-V) relationship (Fig. 4A) . To test whether anchoring of PKA near Ca 2ϩ channels is required for ␤-adrenergic receptor regulation of I Ca in rat ventricular myocytes, we examined the effects of HT31, a specific peptide inhibitor of PKA-AKAP interactions (48) , on the response of I Ca to isoproterenol. Inclusion of HT31 (100 M) in the patch pipette substantially reduced the isoproterenol-induced increase in I Ca (Fig. 4B ) and blocked the hyperpolarizing shift in the voltage-dependence of activation. The mean increase measured at 10 mV was 1.68 Ϯ 0.11-fold in the absence of peptide compared with 1.01 Ϯ 0.10-fold in the presence of HT31. Interestingly, the presence of HT31 also produced a small, but consistent, decrease in basal I Ca . Thus, it seems that PKA anchoring close to Ca 2ϩ channels via an AKAP is required for PKA regulation of cardiac Ca V 1.2 channels under basal conditions and during stimulation of the ␤-adrenergic receptorsignaling pathway by isoproterenol.
We next examined the functional importance of AKAP15 binding to the C-terminal domain of Ca V 1.2. The synthetic peptide corresponding to the LZ motif of AKAP15 [AKAP15 LZ (38 -54) ] was introduced into the intracellular pipette solution. This peptide, which prevents AKAP15 association with the C terminus of the Ca V 1.1 channel, has been used successfully as a competing peptide to prevent PKA-and voltagedependent potentiation of Ca 2ϩ channel activity in skeletal muscle (44) . In cells dialyzed with AKAP15 LZ (38 -54) (100 M), the isoproterenol-induced increase in I Ca was greatly reduced (1.21 Ϯ 0.17-fold), and the hyperpolarizing shift in the voltage dependence of activation was blocked (Fig. 4C) . In contrast, dialysis of a mutant form of the same peptide, in which alanine residues were substituted for the two critical leucine residues [AKAP15 LZm (38 -54) ], had no significant effect on the increase in I Ca induced by isoproterenol 1.55 Ϯ 0.21-fold (Fig. 4D) . Thus, our data show that targeting of PKA to Ca 2ϩ channels via an LZ-like interaction between AKAP15 and the C-terminal domain of Ca V 1.2 channels plays an essential role in ␤-adrenergic receptor regulation of Ca 2ϩ currents in rat ventricular myocytes. Remarkably, the block of PKA regulation is essentially complete, indicating that PKA not bound to AKAP15 is ineffective in regulation of Ca V 1.2 channels in ventricular myocytes in response to activation of the ␤-adrenergic receptor pathway.
Regulation of the CaV1 Family of Ca 2؉ Channels by PKA and AKAP15.
In the present study, we have identified AKAP15 as the anchoring protein important for targeting of PKA to Ca V 1.2 channels and regulating L-type Ca 2ϩ currents in the heart in response to ␤-adrenergic stimulation. AKAP15 directly associates with the C terminus of the cardiac Ca V 1.2 channel through modified LZ motifs and colocalizes with Ca V 1.2 channels in isolated ventricular myocytes. This association is specific for AKAP15 because neither mAKAP nor yotiao, which interact with the RyR (43, 49) and KNCQ1-KNCE1 potassium channel (50), respectively, was detected in Ca V 1.2 channel complexes. Disruption of PKA anchoring to Ca V 1.2 channels via AKAP15 using competing peptides markedly inhibits PKA regulation of Ca V 1.2 currents in ventricular myocytes. Our results identify a conserved LZ motif in the C terminus of the Ca V 1 family of Ca 2ϩ channels that directly anchors an AKAP15-PKA signaling complex to Ca V 1.2 channels and is necessary for efficient ␤-adrenergic regulation of Ca 2ϩ currents in ventricular myocytes. The importance of PKA anchoring through the association with AKAPs for Ca 2ϩ channel regulation was first established for skeletal muscle Ca 2ϩ channels (36, 37) . In skeletal muscle, AKAP15 has been identified as the anchoring protein that targets PKA to Ca V 1.1 channels (38) , and PKA-dependent potentiation of Ca 2ϩ channel activity in skeletal muscle cells is effectively blocked by peptides that disrupt the Ca V 1.1-AKAP15 interaction (39, 44) . In contrast to cardiac and skeletal muscle, PKA is associated with Ca V 1.2 channels via the microtubule-associated protein MAP2B in the brain (42) . In addition, AKAP79͞150 is also expressed in the brain and has been implicated in PKA-independent trafficking of Ca V 1.2 channels (51). Because AKAP15 and Ca V 1.2 channels are both present in the dendrites and cell bodies of brain neurons (52, 53) , it is possible that AKAP15 may be involved in PKA regulation of Ca V 1.2 channels in neurons as well. Moreover, because Ca V 1.3 and Ca V 1.4 channels also contain the conserved AKAP15-binding domain, regulation of these channels in neurons, endocrine cells, cardiac pacemaker cells, retinal rods and cones, and auditory hair cells may also involve the direct targeting of PKA by AKAP15. Anchoring of an AKAP15-PKA-signaling complex to the C terminus of the Ca V 1 family of Ca 2ϩ channels via LZ motifs may define a general mechanism for the precise targeting of PKA for regulation of L-type Ca 2ϩ currents.
Molecular Mechanism of PKA Regulation of CaV1.2 Channels. Despite much effort, it has not been possible to fully reconstitute ␤-adrenergic regulation or PKA regulation of holomeric Ca V 1.2 channels in nonmuscle cells (e.g., refs. [54] [55] [56] . Small increments in Ca V 1.2 channel activity have been observed, but typically Ͻ10% of the increases in I Ca that were observed in cardiac myocytes. Our present results reveal new complexity in PKA regulation of Ca V 1.2 channels. PKA anchoring by AKAP15 is required for regulation, and its interaction site is in the distal C terminus that is proteolytically cleaved in vivo. Effective regulation apparently requires continued association of the distal C-terminal domain, AKAP15, and PKA with the Ca V 1.2 channel. Other essential regulatory proteins may also be associated with this domain. Effective reconstitution of PKA regulation of Ca V 1.2 channels may therefore require reestablishment of these protein-protein interactions in nonmuscle cells.
